
Sign up to save your podcasts
Or
While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious?
Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia
Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest
Emmy award-winning journalist John Donvan moderates
Learn more about your ad choices. Visit podcastchoices.com/adchoices
4.6
20882,088 ratings
While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious?
Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia
Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest
Emmy award-winning journalist John Donvan moderates
Learn more about your ad choices. Visit podcastchoices.com/adchoices
5,001 Listeners
4,224 Listeners
32,131 Listeners
2,252 Listeners
781 Listeners
26,353 Listeners
2,385 Listeners
10,665 Listeners
889 Listeners
6,735 Listeners
809 Listeners
728 Listeners
15,272 Listeners
8,558 Listeners
271 Listeners